Physician profile
Edwin D Christensen
NPI 1689635245
$3,182.60
in general payments reported to CMS, 2019-2025
35 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $557 · 2021: $687 · 2022: $634 · 2023: $525 · 2024: $326 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $570.24 | 2021-2025 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $440.10 | 2019-2024 | Trelegy Ellipta |
| Galderma Laboratories, L.P. | $428.24 | 2022-2025 | Dysport |
| Janssen Pharmaceuticals, INC | $232.90 | 2019-2022 | |
| Novo Nordisk INC | $217.79 | 2019-2022 | |
| Astellas Pharma US INC | $164.84 | 2019-2021 | |
| Vifor Pharma, INC. | $125.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $123.05 | 2020-2022 | |
| Exact Sciences Corporation | $111.74 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $88.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.36 | 2020-2022 | |
| Pfizer INC. | $69.89 | 2019-2021 | |
| Lilly USA, LLC | $51.43 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $39.97 | 2022-2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $35.73 | 2024 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.63 | 2019 | |
| Amarin Pharma, INC. | $31.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.12 | 2023-2025 | Farxiga |
| Currax Pharmaceuticals LLC | $29.72 | 2023-2024 | Contrave |
| Hikma Pharmaceuticals USA | $29.42 | 2019 | |
| Amgen INC. | $24.43 | 2019 | |
| Axsome Therapeutics, INC. | $21.57 | 2024 | Auvelity |
| Tolmar, INC. | $21.50 | 2024 | |
| Abbott Laboratories | $21.40 | 2023 | Freestyle Libre 2 |
| Dexcom, INC. | $19.76 | 2021 | |
| Gilead Sciences, INC. | $18.38 | 2020 | |
| Aytu Biopharma, INC. | $18.30 | 2020 | |
| Shire North American Group INC | $14.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.69 | 2021 | |
| Merck Sharp & Dohme LLC | $14.26 | 2020 | |
| Irhythm Technologies, INC. | $13.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.17 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $13.16 | 2021 | |
| Horizon Therapeutics Plc | $13.14 | 2021 | |
| Esperion Therapeutics, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.